Lipid nanoparticles driving mRNA vaccine innovations: From concept to clinic

Basit Öğe Kaydı
dc.authorscopusidAli Zarrabi / 23483174100
dc.authorwosidAli Zarrabi / GSA-3718-2022
dc.contributor.authorHariri, Amirali
dc.contributor.authorMirian, Mina
dc.contributor.authorZarepour, Atefeh
dc.contributor.authorKhosravi, Arezoo
dc.contributor.authorIravani, Siavash
dc.contributor.authorZarrabi, Ali
dc.date.accessioned2025-06-10T09:05:33Z
dc.date.available2025-06-10T09:05:33Z
dc.date.issued2025
dc.departmentİstinye Üniversitesi, Mühendislik ve Doğa Bilimleri Fakültesi, Biyomedikal Mühendisliği Bölümü
dc.description.abstractMessenger RNA (mRNA) vaccines have emerged as a transformative approach to immunization, driven by their ability to encode specific proteins that elicit targeted immune responses. However, the inherent instability of mRNA and its vulnerability to enzymatic degradation have necessitated the development of sophisticated delivery systems. This review explores the latest advancements in non-viral nanoparticle platforms-particularly lipid nanoparticles (LNPs), cationic liposomes, and lipid-polymer hybrids-for the efficient and safe delivery of mRNA. We analyze the structural and functional components of these nanoplatforms such as ionizable lipids, phospholipids, and PEGylated lipids, which enhance mRNA stability, circulation, and cellular uptake. Key challenges, including immunogenicity, cytotoxicity, and the "PEG dilemma" are examined alongside emerging solutions such as stimuli-responsive elements and targeted ligand modifications. Special emphasis is placed on microfluidic synthesis as a scalable production technique for generating uniform, clinically viable mRNA-loaded nanoparticles. By integrating insights from nanotechnology, immunology, and clinical medicine, this review highlights the critical innovations and ongoing challenges that shape the future of mRNA vaccine development. The conclusions drawn underscore the pivotal role of nanoparticle-based delivery systems in maximizing mRNA vaccine efficacy and advancing personalized immunization strategies against infectious diseases and cancer. ©
dc.identifier.citationHariri, A., Mirian, M., Zarepour, A., Khosravi, A., Iravani, S., & Zarrabi, A. (2025). Lipid nanoparticles driving mRNA vaccine innovations: From concept to clinic. Applied Materials Today, 44, 102786.
dc.identifier.doi10.1016/j.apmt.2025.102786
dc.identifier.issn23529407
dc.identifier.scopusqualityQ1
dc.identifier.urihttp://dx.doi.org/10.1016/j.apmt.2025.102786
dc.identifier.urihttps://hdl.handle.net/20.500.12713/7298
dc.identifier.volume44
dc.indekslendigikaynakScopus
dc.indekslendigikaynakWeb of Science
dc.institutionauthorZarrabi, Ali
dc.institutionauthoridAli Zarrabi / 0000-0003-0391-1769
dc.language.isoen
dc.publisherElsevier Ltd
dc.relation.ispartofApplied Materials Today
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectCationic Lilosomes
dc.subjectLipid Nanoparticles (LNPs)
dc.subjectLipid Nanoparticles
dc.subjectMicrofluidic Synthesis
dc.titleLipid nanoparticles driving mRNA vaccine innovations: From concept to clinic
dc.typeOther

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
1-s2.0-S2352940725002057-main.pdf
Boyut:
17.42 MB
Biçim:
Adobe Portable Document Format
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Biyomedikal Mühendisliği Bölümü Diğer Yayınlar Koleksiyonu